Yan M, Liu Q
Front Med. 2023; 17(4):796-803.
PMID: 36913173
DOI: 10.1007/s11684-022-0975-5.
Tari H, Kessler K, Trahearn N, Werner B, Vinci M, Jones C
Cell Rep. 2022; 40(9):111283.
PMID: 36044867
PMC: 9449134.
DOI: 10.1016/j.celrep.2022.111283.
Jacques F, Baratchart E, Pienta K, Hammarlund E
Med Oncol. 2022; 39(11):160.
PMID: 35972622
PMC: 9381480.
DOI: 10.1007/s12032-022-01740-w.
Servidei T, Lucchetti D, Navarra P, Sgambato A, Riccardi R, Ruggiero A
Cancers (Basel). 2021; 13(23).
PMID: 34885210
PMC: 8657076.
DOI: 10.3390/cancers13236100.
Chan D, Buczacki S
Oncogenesis. 2021; 10(7):53.
PMID: 34272358
PMC: 8285471.
DOI: 10.1038/s41389-021-00342-x.
The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma-HER2 Protein and Gene in Pancreatic Cancer.
Han S, Ryu K, Kwon A
Diagnostics (Basel). 2021; 11(4).
PMID: 33916543
PMC: 8065582.
DOI: 10.3390/diagnostics11040653.
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression.
Luond F, Tiede S, Christofori G
Br J Cancer. 2021; 125(2):164-175.
PMID: 33824479
PMC: 8292450.
DOI: 10.1038/s41416-021-01328-7.
The role of clonal communication and heterogeneity in breast cancer.
Martin-Pardillos A, Valls Chiva A, Bande Vargas G, Hurtado Blanco P, Pineiro Cid R, Guijarro P
BMC Cancer. 2019; 19(1):666.
PMID: 31277602
PMC: 6612119.
DOI: 10.1186/s12885-019-5883-y.
Biology of Nodal Spread in Colon Cancer: Insights from Molecular and Genetic Studies.
Kandagatla P, Maguire L, Hardiman K
Eur Surg Res. 2018; 59(5-6):361-370.
PMID: 30537705
PMC: 6542270.
DOI: 10.1159/000494832.
Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.
Farmanbar A, Firouzi S, Makalowski W, Kneller R, Iwanaga M, Utsunomiya A
Neoplasia. 2018; 20(9):883-893.
PMID: 30032036
PMC: 6074008.
DOI: 10.1016/j.neo.2018.07.001.
Metastasis Seeding Cells: Lone Invaders or Mass Migrators?.
Gerlinger M
Clin Cancer Res. 2018; 24(9):2032-2034.
PMID: 29386220
PMC: 5933519.
DOI: 10.1158/1078-0432.CCR-17-3644.
NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH Cancer Stem-like Cells.
House C, Jordan E, Hernandez L, Ozaki M, James J, Kim M
Cancer Res. 2017; 77(24):6927-6940.
PMID: 29074539
PMC: 5732863.
DOI: 10.1158/0008-5472.CAN-17-0366.
Perspective: Neuroregenerative Nutrition.
Steindler D, Reynolds B
Adv Nutr. 2017; 8(4):546-557.
PMID: 28710142
PMC: 5502873.
DOI: 10.3945/an.117.015388.
Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells.
Andrade S, Sumikawa J, Castro E, Batista F, Paredes-Gamero E, Oliveira L
Oncotarget. 2017; 8(10):16851-16874.
PMID: 28187434
PMC: 5370006.
DOI: 10.18632/oncotarget.15170.
Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer.
Kim S, Kim B, Song Y
Cancer Sci. 2016; 107(9):1173-8.
PMID: 27297561
PMC: 5021036.
DOI: 10.1111/cas.12987.
Learning about the Importance of Mutation Prevention from Curable Cancers and Benign Tumors.
Wang G, Chen L, Yu B, Zellmer L, Xu N, Liao D
J Cancer. 2016; 7(4):436-45.
PMID: 26918057
PMC: 4749364.
DOI: 10.7150/jca.13832.
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.
Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F
Nat Commun. 2015; 6:8305.
PMID: 26392303
PMC: 4595628.
DOI: 10.1038/ncomms9305.
Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.
Morkel M, Riemer P, Blaker H, Sers C
Oncotarget. 2015; 6(25):20785-800.
PMID: 26299805
PMC: 4673229.
DOI: 10.18632/oncotarget.4750.
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer.
Blagden S
Front Oncol. 2015; 5:149.
PMID: 26175968
PMC: 4485078.
DOI: 10.3389/fonc.2015.00149.
Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity.
McBride M, Rida P, Aneja R
Mol Aspects Med. 2015; 45:3-13.
PMID: 26024970
PMC: 4780421.
DOI: 10.1016/j.mam.2015.05.001.